Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional

Status Completed

Clinical Trial Summary

RATIONALE: Megestrol and /or an omega-3 fatty acid-enriched nutritional supplement may improve cancer-related weight loss and lack of appetite. It is not yet known whether megestrol alone, an omega-3 fatty acid-enriched nutritional supplement alone, or a combination of both is most effective in treating cancer-related weight loss and loss of appetite.

PURPOSE: Randomized phase III trial to compare the effectiveness of megestrol with or without an omega-3 fatty acid-enriched nutritional supplement to that of the omega-3 fatty acid-enriched nutritional supplement alone in treating patients who have cancer-related weight loss and lack of appetite.

Clinical Trial Description

OBJECTIVES:

- Compare the appetite-stimulating properties of megestrol vs an eicosapentaenoic acid-enriched nutritional supplement vs both, in terms of patient weight, rate of weight change, and appetite, in patients with cancer-related cachexia and anorexia.

- Determine the effect of these regimens on nausea and vomiting in these patients.

- Assess quality of life in patients treated with these regimens.

- Determine the toxic effects of these regimens in these patients.

- Compare overall survival of patients treated with these regimens.

- Correlate interleukin-6 concentration changes with appetite and weight changes in patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to primary cancer (lung vs gastrointestinal vs other), severity of weight loss in the past 2 months (less than 10 pounds vs 10 pounds or more), planned concurrent chemotherapy (yes vs no), age (under 50 vs 50 and over), and prognosis (good vs bad vs unsure). Patients are randomized to 1 of 3 treatment arms. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00031707
Study type	Interventional
Source	Alliance for Clinical Trials in Oncology
Contact
Status	Completed
Phase	Phase 3
Start date	March 2000
Completion date	January 2004

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05603585` - Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients	N/A
Recruiting	`NCT06206785` - Resting Energy Expenditure in Palliative Cancer Patients
Enrolling by invitation	`NCT05028192` - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Completed	`NCT01696604` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects	Phase 1
Recruiting	`NCT04627376` - Multimodal Program for Cancer Related Cachexia Prevention	N/A
Completed	`NCT02567773` - Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078	Phase 1
Completed	`NCT00866970` - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia	Phase 2
Active, not recruiting	`NCT00710632` - Screening to Predict Weight Loss in Patients With Cancer	N/A
Completed	`NCT00031785` - Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer	Phase 3
Withdrawn	`NCT02017925` - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation	N/A
Recruiting	`NCT01829880` - Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure	N/A
Completed	`NCT01419145` - A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study	N/A
Completed	`NCT01692990` - Study on the Effect of Fish Oil and Appetite	Phase 0
Completed	`NCT01015274` - Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
Terminated	`NCT00851448` - Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients	N/A
Terminated	`NCT00962234` - Metabolism of Lipids in Advanced Cancer	N/A
Completed	`NCT00994669` - Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients	N/A
Completed	`NCT00972634` - Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer	N/A
Terminated	`NCT00558558` - Haelan and Nutrition in Cancer Patients	Phase 2
Terminated	`NCT00535015` - Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms